(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of -1.14% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.05%.
Becton Dickinson & Co's revenue in 2026 is $21,366,000,000.On average, 18 Wall Street analysts forecast BDX's revenue for 2026 to be $5,334,738,207,147, with the lowest BDX revenue forecast at $5,146,819,635,933, and the highest BDX revenue forecast at $5,598,981,476,640. On average, 18 Wall Street analysts forecast BDX's revenue for 2027 to be $5,487,938,684,559, with the lowest BDX revenue forecast at $5,272,466,070,645, and the highest BDX revenue forecast at $5,849,447,724,783.
In 2028, BDX is forecast to generate $5,701,758,055,911 in revenue, with the lowest revenue forecast at $5,377,446,973,332 and the highest revenue forecast at $6,146,755,845,516.